Activist Investor 13D, 13G Filings


This page shows a list of all the recent 13D/G filings made by QVT Financial LP. Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

DateForm Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2018‑10‑10 SC 13D AXON / Axovant Sciences Ltd. 89,285,714 22,703,669 -74.57 75.6 3.42
2018‑06‑07 SC 13D/A AXON / Axovant Sciences Ltd. 75,000,000 89,285,714 19.05 73.1 -3.31
2018‑02‑14 SC 13G/A PTN / Palatin Technologies, Inc. 14,102,011 5,096,095 -63.86 2.54 -74.57
2018‑02‑14 SC 13G/A PDVW / pdvWireless, Inc. 894,031 516,274 -42.25 3.57 -42.70
2018‑02‑14 SC 13G/A AGEN / Agenus Inc. 4,455,874 3,201,263 -28.16 3.2 -37.01
2018‑01‑16 SC 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540 0.00
2017‑10‑17 SC 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540 0.00 29.1 -0.68
2017‑10‑17 SC 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 29.1
2017‑02‑21 SC 13G/A ZX / China Zenix Auto International Ltd. 0 0.0
2017‑02‑10 SC 13G MYOV / Myovant Sciences Ltd. 37,231,342 61.8
2017‑02‑10 SC 13G/A MYOV / Myovant Sciences Ltd. 37,231,342 37,231,342 0.00 61.8 0.00
2017‑02‑09 SC 13G/A AEHR / Aehr Test Systems 1,410,548 1,847,215 30.96 9.99 0.00
2017‑02‑09 SC 13G/A PTN / Palatin Technologies, Inc. 6,997,532 14,102,011 101.53 9.99 0.00
2017‑02‑09 SC 13G/A PDVW / pdvWireless, Inc. 864,301 894,031 3.44 6.23 2.98
2017‑02‑09 SC 13G/A OCRX / Ocera Therapeutics, Inc. 1,058,787 1,032,957 -2.44 4.44 -13.45
2017‑02‑09 SC 13G/A CYTR / CytRx Corp. 5,850,399 0 -100.00 0.0 -100.00
2017‑02‑03 SC 13G AGEN / Agenus Inc. 2,680,321 4,455,874 66.24 5.08 63.87
2016‑11‑28 SC 13G HUNTU / Hunter Maritime Acquisition Corp. Unit 1,000,000 6.67
2016‑08‑22 SC 13G SQNM / Sequenom, Inc. 6,320,963 5.03
2016‑07‑14 SC 13D ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540 0.00 29.3 0.00
2016‑07‑13 SC 13D AXON / Axovant Sciences Ltd. 75,000,000 75.6
2016‑07‑13 SC 13D ABUS / Arbutus Biopharma Corporation 0 16,013,540 0.00 29.3
2016‑02‑17 SC 13D/A ABUS / Arbutus Biopharma Corporation 0 0.0
2016‑02‑17 SC 13G PDVW / pdvWireless, Inc. 864,301 6.05
2016‑02‑16 SC 13G/A MRTX / Mirati Therapeutics, Inc. 429,030 2.21
2016‑02‑16 SC 13G/A CASC / Cascadian Therapeutics, Inc. 0 4,985,702 4.99
2016‑02‑11 SC 13G/A PTN / Palatin Technologies, Inc. 6,997,532 9.99
2016‑02‑11 SC 13G/A RTRX / Retrophin, Inc. 0 229,753 0.63
2016‑02‑11 SC 13G/A ASMB / Assembly Biosciences, Inc. 535,000 3.11
2016‑02‑10 SC 13G/A ARWR / Arrowhead Pharmaceuticals, Inc. 1,951,382 3.27
2016‑02‑10 SC 13G/A OCRX / Ocera Therapeutics, Inc. 1,039,651 1,058,787 1.84 5.13 -1.35
2016‑02‑10 SC 13G/A AGEN / Agenus Inc. 2,680,321 3.1
2016‑02‑10 SC 13G/A CYTR / CytRx Corp. 5,850,399 8.8
2015‑10‑23 SC 13G OCRX / Ocera Therapeutics, Inc. 1,039,651 5.2
2015‑04‑20 SC 13G AEHR / Aehr Test Systems 1,410,548 9.99
2015‑03‑16 SC 13D ABUS / Arbutus Biopharma Corporation 16,013,540 34.4